Isabelle Sinapi

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Robin Kate Kelley, Makoto Ueno, Changhoon Yoo et al. · The Lancet · 2023 · 891 citations · Full text

Urology, Surgical Oncology, Gastrointestinal Oncology +5

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo et al. · The Lancet Oncology · 2019 · 276 citations · Full text

First-line Therapy, Gastrointestinal Oncology, Medicine +6

Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies

Anna Patrikidou, Isabelle Sinapi, Hélène Regnault et al. · Investigational New Drugs · 2014 · 30 citations

Hepatocellular Carcinoma, Medicine, Anti-angiogenic Therapies +8

Interim analysis of the AVETUXIRI Trial: Avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC)—A proof of concept, open-label, nonrandomized phase IIa study.

Marc Van den Eynde, Nicolas D. Huyghe, Astrid De Cuyper et al. · Journal of Clinical Oncology · 2021 · 29 citations · Full text

Avetuxiri Trial, Immunology, Immunoediting +19

397P R-IMMUNE interim analysis: A phase Ib/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with localized rectal cancer

Javier Carrasco, D Schröder, Isabelle Sinapi et al. · Annals of Oncology · 2021 · 26 citations · Full text

Medicine, R-immune Interim Analysis, Immunology +8